natgillin/translations-raw huggingface dataset:
The syringe inside the pen is made from clear type I glass with a stainless steel 27 gauge ½ inch needle and an inner rubber needle cap, containing 1.0 ml of solution.
Brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečega jekla velikosti 27 G, ½ palca, in notranjim gumijastim pokrovčkom igle, ter vsebuje 1,0 ml raztopine.
Pairwise comparison p-values: † = p < 0.05 for comparisons of etanercept + methotrexate vs. methotrexate and ϕ = p < 0.05 for comparisons of etanercept + methotrexate vs. etanercept.
Vrednosti p za primerjavo po parih: † = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z metotreksatom in φ = p < 0,05 za primerjavo kombinacije etanercept + metotreksat z etanerceptom.
One hundred and twelve (112) patients were randomised to receive a dose of 25 mg of etanercept (n = 57) or placebo (n = 55) twice a week for 24 weeks.
Randomizirali so sto dvanajst (112) bolnikov, ki so 24 tednov dvakrat na teden dobivali25 mg odmerek etanercepta (n = 57) ali placebo (n = 55).
4 pre-filled SensoReady pens.
4 napolnjeni injekcijski peresniki SensoReady.
The possibility exists for TNF-antagonists, including Erelzi, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses.
Za antagoniste TNF, vključno z zdravilom Erelzi, velja, da lahko vplivajo na naravno odpornost bolnika proti okužbam in malignim obolenjem, saj TNF sodeluje pri vnetju in uravnava celični imunski odziv.
Before your injection:
Pred injiciranjem:
A higher rate of major birth defects was observed in one observational study comparing pregnancies exposed to etanercept (n = 370) during the first trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n = 164) (adjusted odds ratio 2.4, 95% CI: 1.0 - 5.5).
V 1 opazovalni študiji, kjer so primerjali nosečnosti, izpostavljene etanerceptu (n = 370) v prvem trimesečju, z nosečnostmi, ki niso bile izpostavljene etanerceptu ali drugim antagonistom TNF (n = 164), so opazili večji delež resnih prirojenih napak (prilagojeno razmerje obetov 2,4, 95 % IZ: 1,0-5,5).
Not included in the carton:
Pripomočki, ki niso priloženi:
Clinical efficacy results at 12 months: comparison of etanercept vs. methotrexate vs. etanercept in combination with methotrexate in patients with RA of 6 months to 20 years duration
Rezultati klinične učinkovitosti po 12 mesecih: primerjava med etanerceptom, metotreksatom in kombinacijo etanercepta in metotreksata pri bolnikih z RA, ki je trajal 6 mesecev do 20 let
• A needle-free AI device for demonstration will be available for patient practice use.
• bolnikom bo za vajo na voljo predstavitveni avtoinjektor brez igle.
• The pen can now be removed.
• Zdaj lahko injekcijski peresnik odstranite s kože.
Clear type I glass syringe with a stainless steel 27 gauge ½ inch needle with a needle guard with finger flange, rubber needle cap and plastic plunger, containing 0.5 ml or 1.0 ml of solution.
Zdravilo Erelzi raztopina za injiciranje v napolnjeni injekcijski brizgi Injekcijska brizga iz prozornega stekla tipa I z iglo iz nerjavečega jekla velikosti 27 G, ½ palca, z zapiralom igle in držalom za prste, gumijastim pokrovčkom igle in plastičnim batom, ki vsebuje 0,5 ml ali 1,0 ml raztopine.
Serious infections (including pneumonia, cellulitis, arthritis bacterial, sepsis and parasitic infection)*
celulitisom, bakterijskim artritisom, sepso in parazitsko okužbo)*
37% †, ϕ
18 % 37 %†,φ
• Anti-diabetic medicines: Tell your doctor if you or the child have diabetes or are taking medicines to treat diabetes.
• Zdravila za zdravljenje sladkorne bolezni: Povejte zdravniku, če imate vi ali otrok sladkorno bolezen ali če kateri od vaju jemlje zdravila za zdravljenje sladkorne bolezni.
However, limited safety data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously (see section 5.1).
Vendar pa omejeni podatki o varnosti iz registra bolnikov nakazujejo, da je pri subkutani uporabi zdravila v odmerku 0,8 mg/kg enkrat na teden pri otrocih, starih od 2 do 3 let, varnostni profil podoben profilu pri odraslih in otrocih,
Do not remove the needle cap until just before you give the injection.
Pokrovček igle snemite šele tik pred injiciranjem.
The primary measure of efficacy (ASAS 40) was a 40% improvement in at least three of the four ASAS domains and absence of deterioration in the remaining domain.
Primarno merilo za učinkovitost (ASAS 40) je bilo 40 % izboljšanje vsaj treh od štirih domen ASAS
Instructions for use and handling of the Erelzi pre-filled SensoReady pen Before injection, Erelzi single-use pre-filled pens should be allowed to reach room temperature (approximately 15 to 30 minutes).
Navodila za uporabo in ravnanje z zdravilom Erelzi SensoReady napolnjen injekcijski peresnik Pred injiciranjem je treba napolnjen injekcijski peresnik zdravila Erelzi za enkratno uporabo segreti na sobno temperaturo (počakati približno 15 do 30 minut).
In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady state AUCs were 466 µg•hr/ml and 474 µg•hr/ml for 50 mg etanercept once weekly (N = 154) and 25 mg twice weekly (N = 148), respectively.
Pri analizi populacijske farmakokinetike pri bolnikih z ankilozirajočim spondilitisom so vrednosti AUC etanercepta v stanju dinamičnega ravnovesja pri uporabi etanercepta v odmerku 50 mg enkrat na teden (n = 154) znašale 466 μg·h/ml, pri uporabi etanercepta v odmerku 25 mg dvakrat na teden (n = 148) pa 474 μg·h/ml.
Serious allergic/ anaphylactic reactions (including angioedema, bronchospasm), sarcoidosis
anafilaktične reakcije (vključno z angioedemom in bronhospazmom), sarkoidoza poslabšanje simptomov dermatomiozitisa
In post-marketing experience, approximately half of all of the case reports of opportunistic infections worldwide were invasive fungal infections.
opisanih v poročilih o primerih oportunističnih okužb po vsem svetu, invazivnih glivičnih okužb.
If a caregiver is giving you the injection, the outer upper arms may also be used.
Če vam injekcijo daje negovalec, lahko zdravilo injicira tudi na zunanji strani nadlakti.
Patients weighing 62.5 kg or more may be dosed using a fixed-dose pre-filled syringe or pre-filled pen.
Bolnikom, ki tehtajo 62,5 kg ali več, lahko dajemo odmerke zdravila z napolnjeno injekcijsko brizgo ali napolnjenim injekcijskim peresnikom s stalnim odmerkom.
Adult patients treated with etanercept and anakinra were observed to have a higher rate of serious infection when compared with patients treated with either etanercept or anakinra alone (historical data).
Sočasno zdravljenje z anakinro Pri odraslih bolnikih, zdravljenih z etanerceptom in anakinro, so opazili večjo stopnjo resnih okužb kot pri bolnikih, zdravljenih samo z etanerceptom ali samo z anakinro (retrospektivni podatki).
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Erelzi, they should seek immediate medical advice.
Vse bolnike in starše/skrbnike je treba opozoriti, da morajo pri bolniku v primeru pojava znakov ali simptomov, ki kažejo na krvno diskrazijo ali okužbo (npr. dolgotrajna zvišana telesna temperatura, vnetje žrela, podplutbe, krvavitve,
Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis.
(1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.
Erelzi is only available as 25 mg pre-filled syringe and 50 mg pre-filled syringe and pre-filled pen.
Zdravilo Erelzi je na voljo samo kot 25 mg napolnjena injekcijska brizga in 50 mg napolnjena injekcijska brizga in napolnjen injekcijski peresnik.
Your doctor will determine if Erelzi is an appropriate treatment.
Zdravnik bo presodil o primernosti zdravljenja z zdravilom Erelzi.
This may include a thorough medical history, a chest X-ray and a tuberculin test.
rentgenskim slikanjem prsnega koša in tuberkulinskim testom.
You may also use the lower abdomen, but not the area 5 centimetres around the navel (belly button).
Zdravilo lahko injicirate tudi na spodnjem delu trebuha, vendar ne v predelu, oddaljenem 5 centimetrov ali manj od popka.
• This means the medicine has been delivered.
• To pomeni, da je odmerek zdravila injiciran v celoti.
Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors.
imajo večjo afiniteto za TNF kot monomerni receptorji in so veliko bolj učinkoviti kompetitivni zaviralci vezave TNF na celične receptorje.
• Choose a different site each time you give yourself an injection.
• Vsakokrat, ko si injicirate zdravilo, izberite drugo mesto na koži.
• For enthesitis-related arthritis in patients from the age of 12 years and weighing 62.5 kg or more when other widely used treatments have not worked well enough or are not suitable for them.
• za zdravljenje artritisa, povezanega z entezitisom, pri bolnikih, starejših od 12 let, ki tehtajo 62,5 kg ali več, če zdravljenje z običajnimi oblikami zdravljenja ni bilo uspešno ali jih bolniki niso prenašali.
There have been post-marketing reports of worsening of CHF, with and without identifiable precipitating factors, in patients taking etanercept.
Obstajajo poročila iz obdobja trženja o poslabšanju KSP pri bolnikih, ki jemljejo etanercept, ob prisotnosti dejavnikov, ki bi lahko sprožili tako poslabšanje, in brez njih.
Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), including etanercept, in the post-marketing setting.
Pri otrocih, mladostnikih in mladih odraslih (do 22. leta starosti), ki so se zdravili z antagonisti TNF
Take the blister out of the refrigerator and leave it unopened for about 15-30 minutes so that it reaches room temperature.
Pretisni omot vzemite iz hladilnika in ga pustite zaprtega približno 15-30 minut, da doseže sobno temperaturo.
Adult patients with non-radiographic axial spondyloarthritis
Odrasli bolniki z radiografsko nezaznavnim aksialnim spondilartritisom
Contents of the pack and other information Instructions for Use of the Erelzi SensoReady pen
Vsebina pakiranja in dodatne informacije Navodila za uporabo zdravila Erelzi napolnjen injekcijski peresnik SensoReady
Multipacks contain 12 (3 packs of 4) 25 mg or 50 mg pre-filled syringes or pre-filled pens or 8 (2 packs of 4) or 24 (6 packs of 4) 25 mg pre-filled syringes of Erelzi.
Skupna pakiranja vsebujejo 12 (3 pakiranja s po 4) 25-mg ali 50-mg napolnjenih injekcijskih brizg ali napolnjenih injekcijskih peresnikov ali 8 (2 pakiranji s po 4) ali 24 (6 pakiranj s po 4) 25-mg napolnjenih injekcijskih brizg z zdravilom Erelzi.
The most commonly reported invasive fungal infections included Candida, Pneumocystis, Aspergillus and Histoplasma.
Candida, Pneumocystis, Aspergillus in Histoplasma.
Hepatitis B reactivation, listeria
atipičnimi mikobakterijskimi, virusnimi okužbami in okužbami z reaktivacija hepatitisa B, listerija
Infections and infestations
Infekcijske in parazitske bolezni okužba
For a more comfortable injection, take the pen out of the refrigerator 15-30 minutes before injecting to allow it to reach room temperature.
Da bo injiciranje manj neprijetno, vzemite injekcijski peresnik iz hladilnika 15-30 minut pred injiciranjem, da se lahko ogreje na sobno temperaturo.
Mean serum concentration profiles at steady state in treated RA patients were Cmax of 2.4 mg/l vs. 2.6 mg/l, Cmin of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mg•hr/l vs. 316 mg•hr/l for 50 mg etanercept once weekly (n = 21) vs. 25 mg etanercept twice weekly (n = 16), respectively.
Pri bolnikih z revmatoidnim artritisom so bile povprečne koncentracije v serumu v stanju dinamičnega ravnovesja naslednje: pri zdravljenju z etanerceptom v odmerku 50 mg enkrat na teden (n = 21) je vrednost Cmax znašala 2,4 mg/l, vrednost Cmin 1,2 mg/l, delna AUC pa 297 mg·h/l, pri zdravljenju z etanerceptom v odmerku 25 mg dvakrat na teden (n = 16) pa je vrednost Cmax znašala 2,6 mg/l, vrednost Cmin 1,4 mg/l, delna AUC pa 316 mg·h/l.
This study also showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year of life for infants born to women exposed to etanercept during pregnancy.
prezgodnji porod, mrtvorojenost ali okužbe v prvem letu življenja pri dojenčkih, katerih matere so bile v času nosečnosti izpostavljene etanerceptu.
In order to minimize the risk for the most critical side effects “infection” and “worsening of congestive heart failure” of Erelzi, a Patient Alert Card has been developed.
Opozorilna kartica za bolnika je bila razvita, da bi zmanjšali tveganje za najbolj resne neželene učinke zdravila Erelzi, torej za “okužbo” in “poslabšanje kongestivnega srčnega popuščanja”.
Thus, the combined use of Erelzi and anakinra is not recommended (see sections 4.5 and 4.8).
Ta kombinacija ni pokazala povečane klinične koristi, zato uporaba zdravila Erelzi skupaj z anakinro ni priporočljiva (glejte poglavji 4.5 in 4.8).
• Only remove the cap when you are ready to use the pen.
• Pokrovček snemite šele takrat, ko boste pripravljeni za uporabo injekcijskega peresnika.
For polyarthritis or extended oligoarthritis in patients from the age of 2 years and weighing 62.5 kg or more, or enthesitis-related arthritis or psoriatic arthritis in patients from the age of 12 years and weighing 62.5 kg or more, the usual dose is 25 mg given twice a week or 50 mg given once a week.
Običajni odmerek etanercepta za zdravljenje poliartritisa ali razširjenega oligoartritisa pri bolnikih, starejših od 2 let in ki tehtajo 62,5 kg ali več, in za zdravljenje artritisa, povezanega z entezitisom, ali psoriatičnega artritisa pri bolnikih, starejših od 12 let in ki tehtajo 62,5 kg ali več, je 25 mg dvakrat na teden ali 50 mg enkrat na teden.
These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy.
Take bolnike je treba ves čas zdravljenja in še več tednov po prekinitvi zdravljenja spremljati glede znakov in simptomov aktivne okužbe s HBV. O sočasnem protivirusnem zdravljenju in zdravljenju z zaviralci TNF pri bolnikih, okuženih s HBV, ni zadostnih podatkov.
Etanercept showed statistically significantly greater improvement from baseline to week 12 compared to placebo in most health-related quality of life and physical function assessments, including BASFI (Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 Physical Component Score.
Ankylosing Spondylitis Functional Index; indeks Bath za ocenjevanje aktivnosti ankilizirajočega spondilitisa), rezultatom splošnega zdravstvenega stanja EuroQol 5D in rezultatom telesne komponente SF-36, v primerjavi s placebom.
EU/1/17/1195/008 12 pre-filled syringes
EU/1/17/1195/008 12 napolnjenih injekcijskih brizg
In clinical trials, no interactions have been observed when etanercept was administered with glucocorticoids, salicylates (except sulfasalazine), non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate.
salicilati (razen sulfasalazina), nesteroidnimi protivnetnimi zdravili (NSAIDs), analgetiki ali metotreksatom.
Erelzi is supplied as a pre-filled syringe containing a clear or slightly opalescent, colourless to slightly yellowish solution for injection (injection).
Zdravilo Erelzi je na voljo v napolnjeni injekcijski brizgi, ki vsebuje bistro do rahlo opalescentno, brezbarvno do rahlo rumenkasto raztopino za injiciranje (injekcijo).
Each pack contains 1, 2 or 4 pre-filled syringes with a needle guard, multipacks contain 12 (3 packs of 4) 25 mg or 50 mg pre-filled syringes with a needle guard or 8 (2 packs of 4) or 24 (6 packs of 4) 25 mg pre-filled syringes with a needle guard.
Eno pakiranje vsebuje 1, 2 ali 4 napolnjene injekcijske brizge z zapiralom igle, skupno pakiranje vsebuje 12 (3 pakiranja po 4) 25-mg ali 50-mg napolnjenih injekcijskih brizg z zapiralom igle ali 8 (2 pakiranji po 4) ali 24 (6 pakiranj po 4) 25-mg napolnjenih injekcijskih brizg z zapiralom igle.
Patients currently on methotrexate therapy (stable for ≥ 2 months) could continue at a stable dose of ≤ 25 mg/week methotrexate.
≥ 2 meseca), so lahko nadaljevali s stalnim odmerkom metotreksata ≤ 25 mg/teden.
• Cotton ball or gauze
• kosem vate ali zloženec iz gaze
There have been post-marketing reports of pancytopenia and aplastic anaemia, some of which had fatal outcomes (see section 4.4).
Pancitopenija in aplastična anemija V obdobju trženja so poročali o pancitopeniji in aplastični anemiji, nekateri od teh primerov so bili tudi smrtni (glejte poglavje 4.4).
The efficacy of etanercept in ankylosing spondylitis was assessed in 3 randomised, double-blind studies comparing twice-weekly administration of 25 mg etanercept with placebo.
Odrasli bolniki z ankilozirajočim spondilitisom Učinkovitost etanercepta pri bolnikih z ankilozirajočim spondilitisom je bila ocenjena v 3 randomiziranih dvojno slepih študijah, kjer so primerjali uporabo 25 mg etanercepta dvakrat tedensko s placebom.
Citric acid anhydrous Sodium citrate dihydrate Sodium chloride
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi brezvodna citronska kislina natrijev citrat dihidrat natrijev klorid saharoza
Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Ankilozirajoči spondilitis (AS) Zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, če je bil odziv na konvencionalno zdravljenje nezadosten.
The box contains Erelzi pre-filled syringe(s) individually sealed in a plastic blister.
Erelzi, od katerih je vsaka posebej zapakirana v plastičen pretisni omot.
Re-introduction of treatment with etanercept after discontinuation of up to 24 months resulted in the same magnitudes of responses as patients who received etanercept without interruption of therapy based on results of open-label studies.
Po podatkih iz odprtih študij so bile velikosti odziva po ponovni uvedbi zdravljenja z etanerceptom po prekinitvah, ki so trajale do 24 mesecev, enake kot pri bolnikih, ki so prejemali etanercept brez prekinitve zdravljenja.
At 24 weeks, 56% of patients in the etanercept-treated group had achieved the PASI 75 compared to 5% of placebo-treated patients.
V 24. tednu je 56 % bolnikov doseglo PASI 75 v skupini, zdravljeni z etanerceptom, v skupini s placebom pa 5 %
Post-marketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with etanercept.
Pri bolnikih, zdravljenih z etanerceptom, so v obdobju trženja poročali o zelo redkih primerih karcinoma Merklovih celic.
Differences from adults and other special considerations are discussed in the following paragraphs.
Spodaj so opisane razlike glede na odrasle bolnike in druge posebnosti.
depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.
apendicitis, gastroenteritis, depresija/osebnostne motnje, kožne razjede, ezofagitis/gastritis, streptokokni septični šok (streptokoki skupine A), sladkorna bolezen tipa I in okužbe mehkih tkiv ter postoperativnih ran.
Patients should be tested for HBV infection before initiating treatment with Erelzi.
Pred uvedbo zdravljenja z zdravilom Erelzi je treba bolnike testirati na okužbo s HBV.
Radiographic progression: comparison of etanercept vs. methotrexate vs. etanercept in combination with methotrexate in patients with RA of 6 months to 20 years duration (12 month results)
Radiografsko napredovanje: primerjava med etanerceptom, metotreksatom in kombinacijo etanercepta in metotreksata pri bolnikih z RA, ki je trajal 6 mesecev do 20 let (rezultati pri 12 mesecih)
• Instruction to immediately seek for medical attention after developing or worsening of symptoms for congestive heart failure
• navodilo, da mora bolnik ob pojavu ali poslabšanju simptomov kongestivnega srčnega popuščanja takoj poiskati zdravniško pomoč;
Contents of the pack and other information Instructions for Use of the Erelzi pre-filled syringe (see overleaf)
Vsebina pakiranja in dodatne informacije Navodila za uporabo zdravila Erelzi napolnjena injekcijska brizga
• Use the pen within 5 minutes of removing the cap.
• Po odstranitvi pokrovčka morate injekcijski peresnik uporabiti v roku 5 minut.
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Erelzi therapy (see Vaccinations, above).
opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje (glejte Cepljenja zgoraj).
This device will be provided to HCPs to support (self-) injection training and is intended to be used and trained in the HCP office or during a home care program
Ta pripomoček, namenjen uporabi in poučevanju v ambulanti zdravstvenega delavca oziroma v programu zdravstvene oskrbe na domu, bodo prejeli zdravstveni delavci za pomoč pri usposabljanju za
In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of etanercept and methotrexate did not result in unexpected safety findings, and the safety profile of etanercept when given in combination with methotrexate was similar to the profiles reported in studies of etanercept and methotrexate alone.
V dveletnem nadzorovanem kliničnem preskušanju pri bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z etanerceptom in metotreksatom nepričakovanih ugotovitev glede varnosti;
These included abscess (at various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin infection, skin ulcer, urinary tract infection, vasculitis, and wound infection.
bronhitis, burzitis, celulitis, holecistitis, diareja, divertikulitis, endokarditis (sum nanj), gastroenteritis, hepatitis B, herpes zoster, razjeda na nogi, okužba ustne votline, osteomielitis, otitis, peritonitis,
Radiographic progression at 12 months was significantly less in the etanercept group than in the methotrexate group, while the combination was significantly better than either monotherapy at slowing radiographic progression (see figure below).
Po 12 mesecih zdravljenja je bilo radiografsko napredovanje pri bolnikih, ki so jih zdravili z etanerceptom, statistično pomembno manjše kot pri bolnikih, ki so jih zdravili z metotreksatom; kombinacija obeh zdravil pa je radiografsko napredovanje upočasnila statistično pomembno učinkoviteje kot eno samo zdravilo (glejte spodnjo sliko).
Responses of patients with psoriatic arthritis in a placebo-controlled trial Percent of Patients
Odzivi bolnikov s psoriatičnim artritisom v preskušanju, nadzorovanem s placebom
Multipack: 12 (3 packs of 4) pre-filled SensoReady pens.
raztopina za injiciranje Skupno pakiranje: 12 (3 pakiranja s po 4) napolnjenih injekcijskih peresnikov SensoReady
Remember to take the blister out of the refrigerator and allow it to reach room temperature before preparing it for injection (15-30 minutes).
Pred pripravljanjem brizge za injiciranje ne pozabite pretisnega omota vzeti iz hladilnika in ga pustiti, da doseže sobno temperaturo (15-30 minut).